Immuron Ltd is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that can generate a wide range of products, all with a high safety profile. The versatility of Immuron’s platform is a function of its dairy origin of antibodies, which enables Immuron to commercialize its products through a range of regulatory pathways, including prescription (Rx), medical foods, over-the-counter (OTC) medicines, and dietary supplements. The Company currently markets and sells Travelan® for the prevention of traveler’s diarrhea, while its lead product candidate IMM-124E is in multiple Phase 2 clinical trials for non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and pediatric non-alcoholic fatty liver disease (NAFLD). These products, together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases, address a large unmet need in the market.

Immuron’s IMM-124E is in three Phase 2 clinical trials for NASH, ASH, and pediatric NAFLD. In March 2018, the Company reported positive Phase 2 results of a NASH clinical study. NASH therapies are intended for a global market estimated to be worth $40 billion by 2025, and significant valuations have been afforded to companies in Phase 2 trials for NASH. Intercept Pharmaceuticals had positive Phase 2 results for NASH, leading to an increase in market cap from $1.5 billion to $6.6 billion. Also, companies such as Galectin Therapeutics ($191.5 million), Galmed Pharmaceuticals ($82.0 million), Conatus Pharmaceuticals ($211.5 million), and Genfit SA ($884.8 million), are in Phase 2 trials for NASH and have valuations higher than Immuron.

  • In March 2018, Immuron reported positive top-line Phase 2 results in a NASH clinical study
    • NASH therapies target a global market estimated to be worth $40 billion by 2025
    • Results demonstrate excellent safety and tolerability
    • Statistically significant reduction of additional serum NASH biomarkers associated with liver damage – AST and CK-18
    • Statistically significant reduction in serum endotoxin/lipopolysaccharide (LPS) levels compared to placebo

  • Immuron is in three Phase 2 clinical trials for NASH, ASH, and Pediatric NAFLD

  • Revenue increased 40% to AUD1.4 million in FY17, up from AUD1 million in FY16
    • Current revenue generated from Travelan, an all-natural OTC product for the prevention of traveler’s diarrhea
    • Global market estimate of between $600 million and $1.2 billion for Travelan
    • Currently licensed in the U.S., Australia, Canada, South Africa, Latin America, and several countries in SE Asia

  • IMRN’s IMM-529 program has the potential to be the top therapy for Clostridium difficile infection (CDI)
    • Phase 1 trials to begin at Hadassah Medical center to enroll patients in 2H17; received approval from Israeli Minister of Health
    • Preclinical results showed 80% efficacy for the prevention and treatment of CDI and 77.8% prevention of infection recurrence in mice

More Information | Company Website


Investor Contact Info:

RedChip Companies Inc.
1017 Maitland Center Commons Blvd.
Maitland, FL 32751
(407) 644-4256


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market